CAB uses IHC based evaluation of expression levels of 5 key biomarkers (CD44, N-cadherin, pan-cadherin, ABCC4 and ABCC11) and three clinicopathological prognostic parameters tumor size, tumor grade and node status (as obtained from the medical records from hospitals where these patients were treated) to arrive at a “CAB-Risk Score”. The gene discussed is CDH2; the disease is neoplasm.